Entera Bio (ENTX) Net Margin (2019 - 2025)

Entera Bio's (ENTX) quarterly Net Margin came in at 6235.71% in Q1 2025, down 116.85% on a QoQ basis from 2875.61% in Q4 2024.

Entera Bio (ENTX) Net Margin (2019 - 2025) Analysis & Trends

Entera Bio (ENTX) has 6 years of Net Margin data on file, last reported at 6235.71% in Q1 2025.

Quarterly Net Margin changed N/A year-over-year to 6235.71% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 28383.33% (down 2292698.0% YoY) and the FY2025 annual result came in at 27235.71%, down 2196444.0% from the prior year.
Net Margin retreated to 6235.71% in Q1 2025, from 2875.61% in the prior quarter.
In the past five years, Net Margin ranged from a high of 1462.42% in Q1 2021 to a low of 38337.5% in Q3 2022.
A 4-year average of 8500.23% and a median of 4918.32% in 2022 frame the typical range for Net Margin.
Annual changes were most pronounced in 2021 — Net Margin jumped 377040 bps — and 2022, when it plunged 3604179 bps.
Tracing ENTX's Net Margin over 4 years: stood at 2484.85% in 2021, then slumped by 772 bps to 21678.57% in 2022, then surged by 87 bps to 2875.61% in 2024, then sank by 117 bps to 6235.71% in 2025.
The last three Net Margin figures came in at 6235.71% (Q1 2025), 2875.61% (Q4 2024), and 7192.86% (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.23%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	31.16%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.51%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Entera Bio	161.44 Mn	150.13 Mn	-	-

Download Data